Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease ... Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). 더 보기
CAHmelia-204 Study of 200mg Once-Daily (QD) Tildacerfont in Adult Congenital Adrenal Hyperplasia (CAH) Did Not Achieve Primary Endpoint of Glucocorticoid (GC) Reduction Dose-Ranging Data from...
Topline Data from CAHmelia-204 Study of Tildacerfont in Adult Congenital Adrenal Hyperplasia (CAH) Anticipated in December 2024 Topline Data from CAHptain-205 Study of Tildacerfont in Adult and...
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0504 | 13.710554951 | 0.3676 | 0.4234 | 0.3575 | 528106 | 0.39026809 | CS |
4 | 0.042 | 11.170212766 | 0.376 | 0.4234 | 0.3421 | 427277 | 0.37554922 | CS |
12 | -0.1019 | -19.5999230621 | 0.5199 | 0.574 | 0.3421 | 612342 | 0.43420394 | CS |
26 | -0.035 | -7.72626931567 | 0.453 | 0.608 | 0.3421 | 492941 | 0.45657868 | CS |
52 | -3.122 | -88.1920903955 | 3.54 | 5.95 | 0.3421 | 705085 | 0.99115601 | CS |
156 | -1.922 | -82.1367521368 | 2.34 | 5.95 | 0.3421 | 434425 | 1.58287967 | CS |
260 | -16.582 | -97.5411764706 | 17 | 35.6 | 0.3421 | 546434 | 3.22872249 | CS |
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관